Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α‐galactosidase A activity: A 14‐year follow‐up without enzyme replacement therapy
Open Access
- 12 March 2016
- journal article
- case report
- Published by Wiley in Nephrology
- Vol. 21 (S1) , 57-59
Abstract
We report a case of kidney transplantation from mother to son, both of whom were likely to have had an unrecognized renal variant phenotype of Fabry disease. The patient was a 54‐year‐old man, with an unknown primary cause of end stage renal disease. He had no notable past medical history, other than end stage renal disease. He underwent living‐related kidney transplantation from his mother at age 40 years. Foam cells in the glomeruli were identified on histology assessment of a 0‐hour allograft biopsy, with zebra bodies identified in the glomerular visceral epithelial cells by electron microscopy. These findings were indicative of Fabry disease in the donated kidney. As a definitive diagnosis of Fabry's disease could not be confirmed, enzyme replacement therapy was not initiated. Thirteen years after kidney transplantation, the patient underwent left nephrectomy for a left renal tumour, with pathological findings of clear cell carcinoma, foam cells and zebra bodies in the native kidney. Detailed examinations identified low α‐galactosidase A activity and mutation of the α‐Gal A gene, confirming a diagnosis of a renal variant phenotype of Fabry disease. Histology of several allograft biopsies performed over the 14 years from the time of kidney transplantation revealed only moderate interstitial fibrosis and tubular atrophy, with no evidence of disease progression on electron microscopy, despite the presence of zebra bodies in the glomerular visceral epithelial cells.Keywords
This publication has 9 references indexed in Scilit:
- Kidney Transplant Outcomes in Patients With Fabry DiseaseTransplantation, 2009
- Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJournal of Inherited Metabolic Disease, 2007
- Agalsidase-Beta Therapy for Advanced Fabry DiseaseAnnals of Internal Medicine, 2007
- Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot studyKidney International, 2004
- Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype1Kidney International, 2003
- Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement TherapyAnnals of Internal Medicine, 2003
- Renal pathological changes in Fabry diseaseJournal of Inherited Metabolic Disease, 2001
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyNew England Journal of Medicine, 1995
- Early renal changes in hemizygous and heterozygous patients with Fabry's diseaseKidney International, 1978